While the inhibition of the PI3K/AKT/mTOR and ERK pathways has been investigated in other malignancies, the in vivo impact of this co-targeting strategy for HNSCC has not been well validated. This evidence concerns the gene MAPK1 and head and neck squamous cell carcinoma.